Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Mantle-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Mantle Cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Antirheumatic Agents

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Etoposide

Cytarabine

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Dexamethasone

Prednisone

Rituximab

Vincristine

Cisplatin

Dexamethasone acetate

Etoposide phosphate

Thalidomide

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antineoplastic Agents, Immunological

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antimetabolites

Antiviral Agents

Tubulin Modulators

Antimitotic Agents

Angiogenesis Inhibitors

Growth Inhibitors

Shuhua Yi, Doc

Lugui Qiu, Doc

The purpose of this study is to:

1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years);
2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.

Enrolled patients will receive EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) ±R /DHAP(cisplatin, cytarabine and dexamethasone) ±R alternating chemotherapy. If a partial remission or better response achieves, patients will be recommended to receive autologous stem cell transplantation as consideration therapy or another two cycles EDOCH ±R /DHAP±R chemotherapy (based on patient's choice). Patients with less than partial remission (PR) response will quit this study. After treatments finished, maintenance therapy with rituximab or thalidomide plus prednisone will be given less than two years. The determination of maintenance regimens is dependent on patients choices.

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial

the time interval between diagnosis and disease progression or death or last follow-up

measure with normal serum immunofixation electrophoresis and normal bone marrow feature, and without symptoms and enlarged organs

time interval between diagnosis and death or last follow-up

Institute of Hematology & Blood Diseases Hospital, China

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
EDOCH Alternating With DHAP for New Diagnosed Younger MCL	NCT02858804	Mantle Cell Lym...	Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
EDOCH Alternating With DHAP for New Diagnosed Younger MCL	NCT02858804	Mantle Cell Lym...	Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
EDOCH Alternating With DHAP for New Diagnosed Younger MCL	NCT02858804	Mantle Cell Lym...	Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China

Spots Global Cancer Trial Database for edoch

Every month we try and update this database with for edoch cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for edoch

Every month we try and update this database with for edoch cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for edoch cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.